Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)
Brief Summary: The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1a (HCV GT1a) infection without cirrhosis.


Options:
A: Arm Label: SOF+RBV+placebo; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV, Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): SOF+RBV+placebo
B: Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Peg-IFN-alfa-2b; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Ribavirin (RBV) tablet; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Ribavirin (RBV) capsule; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule
C: Arm Label: PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV | Arm Label: BI 201335 for 12 or 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI 201335 | Arm Label: Placebo and PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV, Drug: Placebo | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 for 12 or 24 weeks, PegIFN/RBV, Placebo and PegIFN/RBV | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and PegIFN/RBV
D: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for Ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV

Answer: D